The Life Sciences team advised AlloVir, Inc. (Nasdaq: ALVR) on its upsized initial public offering of 18,687,500 shares of common stock, which includes the exercise in full of the underwriters’ option to purchase up to 2,437,500 additional shares of common stock, at a public offering price of $17.00 per share, before underwriting discounts and commissions. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AlloVir, were approximately $317.7 million.
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.
The Goodwin team was led by Danielle Lauzon, and Mitchell Bloom.
For more details, read the press release and articles in FierceBiotech, BioSpace, and Xconomy.